Critical Care Explorations (Apr 2024)

Long-Term Survival of Patients With Cancer, Sepsis, and Vasopressor Requirements Based on Lactate Levels

  • John A. Cuenca, MD,
  • Joseph L. Nates, MD, MBA, MCCM,
  • Andres Laserna, MD,
  • Alba J. Heatter, MD,
  • Nirmala Manjappachar, MD,
  • Peyton Martin, BS,
  • Maria P. Reyes, MD,
  • Mike Hernandez, MS,
  • Jacob Hall, PharmD,
  • Claudia M. Ramirez, MD,
  • Diego H. de Villalobos, MD

DOI
https://doi.org/10.1097/CCE.0000000000001070
Journal volume & issue
Vol. 6, no. 4
p. e1070

Abstract

Read online

A prospective cohort study was conducted to evaluate the 1-year survival of cancer patients with sepsis and vasopressor requirements. Eligible patients were admitted a Comprehensive Cancer Center’s ICU and were compared based on their admission lactate levels. Of the 132 included patients, 87 (66%) had high lactate (HL; > 2.0 mmol/L), and 45 (34%) had normal lactate (NL; ≤ 2.0 mmol/L). The 1-year survival rates of the two groups were similar (HL 16% vs. NL 18%; p = 0.0921). After adjustment for ICU baseline characteristics, HL was not significantly associated with a 1-year survival (Hazards ratio, 1.39; 95% CI, 0.94–2.05). Critically ill cancer patients with sepsis and vasopressor requirements, regardless of the lactate level, had 1-year survival of less than 20%. Large multicenter cancer registries would enable to confirm our findings and better understand the long-term trajectories of sepsis in this vulnerable population.